[EN] ELECTROCHEMICALLY-CLEAVABLE LINKERS<br/>[FR] LIEURS CLIVABLES PAR VOIE ÉLECTROCHIMIQUE
申请人:MICROSOFT TECHNOLOGY LICENSING LLC
公开号:WO2021158412A1
公开(公告)日:2021-08-12
This disclosure provides electrochemically-cleavable linkers with cleavage potentials that are less than the redox potential of the solvent in which the linkers are used. In some applications, the solvent may be water or an aqueous buffer solution. The linkers may be used to link a nucleotide to a bound group. The linkers include a cleavable group which may be one of a methoxybenzyl alcohol, an ester, a propargyl thioether, or a trichloroethyl ether. The linkers may be cleaved in solvent by generating an electrode potential that is less than the redox potential of the solvent. In some implementations, an electrode array may be used to generate localized electrode potentials which selectively cleave linkers bound to the activated electrode. Uses for the linkers include attachment of blocking groups to nucleotides in enzymatic oligonucleotide synthesis.
[EN] COMPOSITIONS AND METHODS FOR SYNTHESIS OF PHOSPHORYLATED MOLECULES<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE SYNTHÈSE DE MOLÉCULES PHOSPHORYLÉES
申请人:UNIV CALIFORNIA
公开号:WO2019195494A1
公开(公告)日:2019-10-10
The invention provides compositions and methods for synthesis of phosphorylated organic compounds, including nucleoside triphosphates.
这项发明提供了合成磷酸化有机化合物的组合物和方法,包括核苷三磷酸。
Method of treating cancer
申请人:——
公开号:US20030220241A1
公开(公告)日:2003-11-27
The present invention relates to methods of treating cancer using a combination of a compound which is a PSA conjugate and a compound which is a inhibitor of prenyl-protein transferase, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound which is a PSA conjugate and a compound which is a inhibitor of prenyl-protein transferase. The invention also relates to methods of preparing such compositions.
[EN] CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS<br/>[FR] ANTAGONISTES DE CCR5 EN TANT QU'AGENTS THÉRAPEUTIQUES
申请人:SMITHKLINE BEECHAM CORP
公开号:WO2009058924A1
公开(公告)日:2009-05-07
The present invention relates to compounds useful in the treatment of CCR5-related diseases and disorders, for example, useful in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).
[EN] NEW FLUORESCENT DYES AND THEIR USES AS BIOMARKERS<br/>[FR] NOUVEAUX COLORANTS FLUORESCENTS ET LEURS UTILISATIONS EN TANT QUE BIOMARQUEURS
申请人:ILLUMINA CAMBRIDGE LTD
公开号:WO2018060482A1
公开(公告)日:2018-04-05
The present application relates to new fluorescent dyes and their uses as fluorescent labels. The compounds may be used as fluorescent labels for nucleotides in nucleic acid sequencing applications.